Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Crosstalk Between Motor and Sensory Nerves Ensures Union

By Drug Discovery Trends Editor | May 7, 2008

  Crosstalk between motor and sensory nerves

Crosstalk between motor (shown in green) and sensory (shown in red) nerves ensures that the two different types of neurons join up after they emerge from the spinal cord either sensory or motor axons. (Source: Benjamin W. Gallarda and Shane E. Andrews, Salk Institute for Biological Studies)

In a study, published in Science, scientists at the Salk Institute for Biological Studies report that constant crosstalk between growing sensory and motor neurons keeps them on track. During embryonic development, nerve cells hesitantly extend tentacle-like protrusions called axons. Growth cones, small enlargements at the axons tip, actively search their local environment for chemical cues that guide them to their target. One such cue comes from a class of molecules called ephrins, which repel cells carrying Eph proteins.

The traditional view was that growth cones studded with Eph proteins search their environments for ephrins, which take on the role of ligands. The Salk researchers discovered that neurons not only carry both types of proteins, but that the role of ephrins and Ephs can change as well.

This article was published in Drug Discovery & Development magazine: Vol. 11, No. 5, May, 2008, pp. 18.


Filed Under: Drug Discovery

 

Related Articles Read More >

Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE